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Background: The objective of this study was to evaluate the effectiveness of various linseed oil (LO) preparations
(oral, topical, oral and topical combined) in treating experimentally induced keratoconjunctivitis sicca (KCS) in
rabbits. Twenty male New Zealand white rabbits were divided into four groups: group C (control), group OLO (oral
LO), group TLO (topical LO), and group OTLO (oral and topical LO). The animals were evaluated weekly using
Schirmer's tear test (STT), fluorescein test (FT), and Rose Bengal test (RBT) and were euthanized at the end of the
experiment for histopathological analysis.
Findings: There were significant improvements in the parameters analyzed (STT, FT, and RBT) and in the
histopathological finding in all of the groups using LO.
Conclusions: The analyzed results demonstrate that LO, administered orally or topically, was effective in treating
experimentally induced KCS in rabbits, although combined oral and topical LO did not show additional benefits
greater than those with a single route of administration.
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Introduction
Keratoconjunctivitis sicca (KCS), or dry eye syndrome, is
characterized by chronic inflammation of the cornea,
conjunctiva, and lacrimal glands caused by quantitative
and/or qualitative tear changes [1]. Recently, several
studies have proven that essential fatty acids (EFAs),
omega-3 (ω-3) and omega-6 (ω-6), administered orally
are an alternative therapy for patients with various types
of tear deficiency, including Sjögren's syndrome and
KCS [2-6]. Additionally, the topical use of ω-3 and ω-6
effectively controlled the signs of experimentally induced
inflammation in rats with KCS [7].
Eicosanoids are biologically active substances that regu-
late physiological processes and are lipid mediators of in-
flammation. From the ω-6 EFA-derived prostanoids,* Correspondence: silviafranco@unoeste.br
6Department of Small Animal Medicine, University of Oeste Paulista
(UNOESTE), Rodovia Raposo Tavares, Km 572, Presidente Prudente, São Paulo
19001-970, Brazil
Full list of author information is available at the end of the article
© 2013 Neves et al.; licensee Springer. This is a
Attribution License (http://creativecommons.or
in any medium, provided the original work is parachidonic acid, via cyclooxygenase 1 (COX1) pro-
inflammatory mediators, is synthesized, including prosta-
glandin (PGE2), thromboxane (TXA2), prostacyclin
(PGI2), and the leukotrienes (LTA4, LTB4, LTC4, and
LTD4). However, non-inflammatory mediators (PGE1 and
TXA1) are also synthesized from the EFA series of ω-6 by
the action of COX1 on dihomo-γ-linoleic acid (DGLA)
and from the EFA series of ω-3 by the action of COX1 on
eicosapentaenoic acid (PGE3, PGI3, and TXA3) as well as
by the actions of lipoxygenase (LTA5, LTB5, LTC5, and
LTD5) and of docosahexaenoic acid [2,4].
The ω-3 and ω-6 EFAs are found in many foods, such
as nuts, cold-water fish, soybeans, rapeseed oil, and lin-
seed oil. Linseed, Linum usitatissimum, is composed of
57% ω-3, 16% ω-6, 28% monounsaturated fatty acids,
and only 9% unsaturated fatty acids, and the ω-3-to-ω-6
ratio of 1:3 is considered close to ideal. Linseed is con-
sidered to be a natural anti-inflammatory agent due its
potential in synthesizing non-inflammatory mediators,
such as PGE1 and TXA1 [8-10]. The objective of thisn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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oil (LO) preparations (oral, topical, oral and topical com-
bined), which are rich in ω-3 and ω-6, in treating experi-
mentally induced KCS in rabbits.
Materials and methods
Twenty male New Zealand white rabbits (Oryctolagus
cuniculus) were housed in individual metal cages with
water and food ad libitum. All of the procedures were
approved by the Ethics Committee on the Use of
Animals of UNOESTE under protocol no. 014/09. The
induction model of KCS in rabbits was based on a previ-
ously published study [11], which described the removal
of the lacrimal glands and nictitating membranes and
the administration of atropine sulfate 1% eye drops TID
until the confirmation of KCS diagnosis (≤5 mm/min
Schirmer's tear test (STT) and/or Rose Bengal test
(RBT) positive) and then throughout the treatmentFigure 1 STT, FT, and RBT results. (A) Mean (±SD) STT values: ≤5 mm/m
(negative - absence of corneal ulcers) and 2 (positive - presence of corneal
stained cells devitalized by KCS) and 2 (presence of stained cells devitalized
LO), and group OTLO (oral + topical LO). The asterisk indicates P < 0.05 (Tuperiod (12 weeks) for KCS maintenance. The rabbits
were evaluated at M0 (prior to the KCS induction sur-
gery), M1 (1 week after the induction of KCS and the
beginning of treatment), and M2 to M12 (i.e., assess-
ments as weekly intervals beginning 1 week after the ini-
tiation of treatment). Of the 20 rabbits, 15 were induced
using the KCS protocol described above and 5 were allo-
cated to the control group without KCS induction. A
week after the induction of KCS, the groups of animals
were treated for 12 weeks as follows: group C (n = 5,
control, one drop of placebo, 0.9% NaCl solution, topic-
ally twice a day (BID) in both eyes), group OLO (n = 5,
1 g/day of liquid LO made by Laboratory Ophthalmos-
SP (São Paulo, Brazil) orally), group TLO (n = 5, one
drop of LO eye drops made by Laboratory Ophthalmos-
SP BID in both eyes), and group OTLO (n = 5, 1 g/day
of liquid LO orally with one drop of LO eye drops BID
in both eyes). STT was performed without anestheticin (KCS positive). (B) Median (quartiles P25 and P75) FT values: 1
ulcers). (C) Median (quartiles P25 and P75) RBT values: 1 (absence of
by KCS). Group C (control), group OLO (oral LO), group OLT (topical
key's test compared to M0).
Figure 2 Rabbit no. 4 from group OTLO (oral and topical LO). (A) A melting ulcer in M1. (B) Partial resolution of the melting ulcer processes
in M12.
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were ≤5 mm/min. The fluorescein test (FT) was per-
formed to observe ulcers colored with 1% fluorescein
strips moistened with a small amount of normal saline;Figure 3 Photomicrography of the cornea and conjunctiva. (A) Group
mass (arrows); PAS, ×100. (B) Group OLO with caliciform cells (large arrows
with mild edema of the epithelium (arrows) and corneal stroma (asterisks);
moderate edema (thin arrow) and the subcorneal area showing moderate
the blood vessel (asterisk); HE, ×100. (E) Group TLO with severe edema in t
stroma (large arrows); HE, ×400. (F) Group TLO with exocytosis of neutroph
(thin arrow) and congestion of blood vessels in the stroma (large arrow); H
(arrows) and stroma showing intense edema; HE, ×400. (H) Group OTLO sh
infiltration (thin arrows), and subconjunctival edema (asterisks); PAS, ×400. (
caliciform cells (large arrows) and lymphocytic inflammatory infiltration witthey were scored 1 (negative for a corneal ulcer) or 2
(positive for a corneal ulcer). RBT was performed on
stained cells devitalized by KCS; after instilling the
anesthetic eye drops, we used one drop of 0.5% RoseC without conjunctival inflammation; caliciform cells were seen in a
) and subconjunctival edema (thin arrows); PAS, ×100. (C) Group TLO
HE, ×100. (D) Group TLO with the corneal epithelium showing
inflammatory infiltration with lymphocytes (large arrow) and stroma in
he corneal and subcorneal epithelium and moderate edema in the
ils in the corneal epithelium and with the presence of neutrophils
E, ×400. (G) Corneal epithelium showing exocytosis of neutrophils
ows the presence of caliciform cells (large arrows), mild inflammatory
I) The conjunctiva of group OTLO group showing the presence of
h conjunctival necrosis (thin arrows); PAS, ×100.
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cells devitalized by KCS) or 2 (the presence of stained
cells devitalized by KCS). For the histopathological ana-
lysis at the end of the experiment (M12), the rabbits
were euthanized using 2.5% IV sodium thiopental (200
mg/kg); after transpalpebral enucleation, the eyeball was
placed in a solution of 10% formaldehyde for 24 to 48 h.
The eyes were stored in 70% alcohol and were pro-
cessed according to the technique for inclusion in paraffin;
5-μm-thick cuts of the cornea and conjunctiva were
obtained, which were colored with hematoxylin and eosin
(HE) as well as periodic acid-Schiff (PAS). For STT vari-
ables and the density of caliciform cells, we used the vari-
ance analysis test for paired samples in contrast to Tukey's
method. For FT, RBT, and histopathology, a non-
parametric Friedman test was used to compare the various
times, and the Kruskal-Wallis test with Dunn's method
was used for between-group comparisons. We adopted a
significance level of P < 0.05.
Results
The STT, FT, and RBT results are shown in Figure 1. An
interesting clinical finding was from rabbit no. 4 of
group OTLO (oral and topical LO), which presented a
melting ulcer at M1, and there was a partial resolution
of the process until the end of the experiment (Figure 2).
The histopathology results of the cornea and conjunctiva
in group C showed no changes (Figure 3A). Upon histo-
pathology of the cornea, there was slight edema in group
OLO (Figure 3B) compared to group TLO, which pre-
sented moderate edema (Figure 3C,D,E). In group TLO,
the presence of inflammatory infiltrates with exocytosis
of neutrophils was observed (Figure 3F,G). In the histo-
pathological results of the conjunctiva, the OLO
(Figure 3B) and OTLO (Figure 3H) groups had mild and
moderate edema, respectively, whereas group TLO had
severe edema. The OLO and OTLO groups (Figure 3I)
showed mild necrosis, whereas group TLO showed
moderate necrosis. There was no statistical significance
(P > 0.05) in the difference in the caliciform or goblet cell
density in the conjunctiva among the groups, and the
values were 9.8 ± 1.9 (C), 9.5 ± 2.3 (OLO), 10.7 ± 2.7
(TLO), and 9.0 ± 3.8 (OTLO).
Discussion and Conclusions
The group treated with oral LO (group OLO) had normal
tear production in the second week after starting treat-
ment and a significant increase above the control group
after 3 weeks. This finding is consistent with several stud-
ies, especially in patients with Sjögren's syndrome, in
whom oral ω-3 and ω-6 supplementation has been recom-
mended to control KCS symptoms [2-4,12]. In this study,
topical LO was more effective in the early treatment of
KCS, increased production of tears, and corneal ulcerresolution. The lipid mediators play an important role in
the resolution and repair of corneal injuries [7,12,13].
The LO mechanism of action might be anti-inflammatory;
the inhibitory response of the arachidonic acid inflam-
matory cascade has been proven to synthesize the non-
inflammatory mediators PGE1 and TXA1 from ω-6
series by the action of COX1 on DGLA, which likely
reduces the inflammation on the cornea, conjunctiva,
and lacrimal glands; increases the production of tears;
and improves the activity of caliciform cells, conse-
quently causing an increase in the production of mucin.
This increased mucin provides an improvement in the
PTF quality, which leads to reduced tear evaporation in
the aqueous portion of the eye [2,4,6,7,12]. In this
study, LO topical instillation did not induce any ocular
side effects, such as irritation, hyperemia, or discomfort.
In addition, the concomitant use of LO orally and top-
ically did not show benefits beyond a single route of
administration. A hypothesis for this result is that an
excess of ω-3 and ω-6 results in an improper ratio of
these two EFAs. More pharmacokinetic and pharmaco-
dynamic studies of oral LO and of LO in ocular topical
formulations should be conducted to clarify these
results. Therefore, we conclude that LO, orally and top-
ically, was effective in treating experimentally induced
KCS in rabbits, although combined oral and topical LO
did not demonstrate additional benefits beyond those
from a single route of administration.
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